A new trading day began on Tuesday, with Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock price up 3.05% from the previous day of trading, before settling in for the closing price of $24.56. APLS’s price has ranged from $16.10 to $35.71 over the past 52 weeks.
During the last 5-year period, the sales growth of Healthcare Sector giant was 20.08%. Meanwhile, its annual earnings per share averaged 115.86%. With a float of $103.76 million, this company’s outstanding shares have now reached $126.50 million.
Apellis Pharmaceuticals Inc (APLS) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 17.99%, while institutional ownership is 99.29%. The most recent insider transaction that took place on Dec 16 ’25, was worth 122,450. Before that another transaction happened on Nov 17 ’25, when Company’s General Counsel sold 5,000 for $20.06, making the entire transaction worth $100,300. This insider now owns 108,730 shares in total.
Apellis Pharmaceuticals Inc (APLS) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.29 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.52 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 115.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 65.31% during the next five years compared to 20.08% growth over the previous five years of trading.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Here are Apellis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.15. Likewise, its price to free cash flow for the trailing twelve months is 40.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.30, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -0.98 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Looking closely at Apellis Pharmaceuticals Inc (NASDAQ: APLS), its last 5-days average volume was 2.16 million, which is a drop from its year-to-date volume of 2.37 million. As of the previous 9 days, the stock’s Stochastic %D was 87.25%.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 56.92%, which indicates a significant decrease from 89.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.00 in the past 14 days, which was lower than the 1.09 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.14, while its 200-day Moving Average is $21.91. However, in the short run, Apellis Pharmaceuticals Inc’s stock first resistance to watch stands at $26.13. Second resistance stands at $26.95. The third major resistance level sits at $28.02. If the price goes on to break the first support level at $24.25, it is likely to go to the next support level at $23.18. Now, if the price goes above the second support level, the third support stands at $22.36.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
With a market capitalization of 3.20 billion, the company has a total of 126,525K Shares Outstanding. Currently, annual sales are 781,370 K while annual income is -197,880 K. The company’s previous quarter sales were 458,580 K while its latest quarter income was 215,720 K.
